Salveen Richter Analyst Performance

Managing Director, Global Investment Research at The Goldman Sachs Group

Salveen Richter is a stock analyst at The Goldman Sachs Group focused in the medical sector, covering 29 publicly traded companies. Over the past year, Salveen Richter has issued 26 stock ratings, including buy, hold, and sell recommendations. While full access to Salveen Richter's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Salveen Richter's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 50 Last 10 Years
Buy Recommendations: 63.83% 30 Buy Ratings
Companies Covered: 29 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	6.4%	2 ratings
Buy	57.4%	27 ratings
Hold	29.8%	14 ratings
Sell	6.4%	2 ratings

Out of 47 total stock ratings issued by Salveen Richter at The Goldman Sachs Group, the majority (57.4%) have been Buy recommendations, followed by 29.8% Hold, 6.4% Strong Buy, and 6.4% Sell.

Best & Worst Calls

Best Call
0000.0%
GEVA
Feb 2015
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
SGEN
Feb 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	96.6% of companies on NASDAQ	28 companies
NYSE	3.4% of companies on NYSE	1 company

Salveen Richter, an analyst at The Goldman Sachs Group, currently covers 29 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 25 companies	86.2%
	Miscellaneous 4 companies	13.8%

Salveen Richter of The Goldman Sachs Group specializes in stock coverage within the Medical sector, with additional focus on companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 17 companies	58.6%
MED - DRUGS 4 companies	13.8%
Miscellaneous 4 companies	13.8%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 2 companies	6.9%
BIOTECHNOLOGY 2 companies	6.9%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
ALNY Alnylam Pharmaceuticals	9/16/2025	Boost Price Target	$461.42	$566.00	Buy
IONS Ionis Pharmaceuticals	9/3/2025	Boost Price Target	$61.17	$45.00	Sell
FDMT 4D Molecular Therapeutics	8/12/2025	Lower Price Target	$6.17	$38.00	Buy
SRPT Sarepta Therapeutics	8/7/2025	Boost Price Target	$17.42	$19.00	Neutral
ACAD ACADIA Pharmaceuticals	8/7/2025	Boost Price Target	$23.89	$17.00	Sell
SRPT Sarepta Therapeutics	6/17/2025	Downgrade	$22.03	$29.00	Hold
ELVN Enliven Therapeutics	6/16/2025	Initiated Coverage	$21.91	$37.00	Buy
FDMT 4D Molecular Therapeutics	5/9/2025	Lower Price Target	$3.06	$44.00	Buy
RCUS Arcus Biosciences	5/8/2025	Lower Price Target	$8.14	$13.00	Neutral
CRSP CRISPR Therapeutics	5/8/2025	Lower Price Target	$35.40	$47.00	Neutral
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
SRPT Sarepta Therapeutics	5/7/2025	Lower Price Target	$37.52	$100.00	Buy
BMRN BioMarin Pharmaceutical	5/5/2025	Lower Price Target	$62.48	$104.00	Buy
FOLD Amicus Therapeutics	5/2/2025	Lower Price Target	$6.56	$9.00	Neutral
REGN Regeneron Pharmaceuticals	4/30/2025	Lower Price Target	$590.09	$804.00	Buy
BIIB Biogen	4/23/2025	Lower Price Target	$120.33	$197.00	Buy
REGN Regeneron Pharmaceuticals	4/14/2025	Lower Price Target	$560.49	$917.00	Buy
ADPT Adaptive Biotechnologies	3/21/2025	Upgrade	$7.75	$9.00	Buy
SMMT Summit Therapeutics	2/28/2025	Initiated Coverage	$18.49	$42.00	Buy
CRSP CRISPR Therapeutics	2/13/2025	Lower Price Target	$42.93	$57.00	Neutral
BIIB Biogen	2/13/2025	Lower Price Target	$136.88	$245.00	Buy
GILD Gilead Sciences	2/12/2025	Boost Price Target	$103.52	$96.00	Neutral
MRNA Moderna	1/29/2025	Downgrade	$44.94	$51.00	Neutral
MRNA Moderna	1/28/2025	Lower Price Target	$43.47	$99.00	Buy
DNLI Denali Therapeutics	1/28/2025	Lower Price Target	$22.99	$40.00	Buy
ADPT Adaptive Biotechnologies	1/28/2025	Boost Price Target	$7.76	$7.50	Neutral
NTLA Intellia Therapeutics	1/14/2025	Lower Price Target	$10.05	$12.00	Neutral

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.